Pagani O, Niman SM, Ruggeri M, Peccatori FA, Azim HA, Colleoni M, Saura C, Shimizu C, Sætersdal AB, Kroep JR, Warner E, Amant F, Mailliez A, Moore HCF, Ruiz-Borrego M, Walshe JM, Borges VF, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Saunders C, Bjelic-Radisic V et al. (2026)
Updated Results of the POSITIVE (Pregnancy Outcome and Safety of Interrupting Therapy for Women with Endocrine Responsive Breast Cancer) Trial
Ann Oncol (in press)
DOI 10.1016/j.annonc.2026.05.699, PubMed 42214557

Ailte I, Chauhan SK, Prasmickaite L, Bassarova AV, Poissonnier A, Feenstra M, Nyakas M, Johannessen B, Ryder T, Hermann R, Frich L, Holth A, Inderberg EM, Jespersen H, Flørenes VA, Kyte JA, Mælandsmo GM, Egeland EV (2026)
CD38^hiCD19^dim cells in lymph nodes predict favorable prognosis in patients with stage III melanoma receiving adjuvant PD-1-blockade
Front Oncol, 16, 1815008
DOI 10.3389/fonc.2026.1815008, PubMed 42158424

Lien TG, Ohnstad HO, Lingjærde OC, Vallon-Christersson J, Aaserud M, Sveli MAT, Borg Å, On Behalf Of Osbreac, Garred Ø, Borgen E, Naume B, Russnes H, Sørlie T (2026)
Correction: Lien et al. Sample Preparation Approach Influences PAM50 Risk of Recurrence Score in Early Breast Cancer. Cancers 2021, 13, 6118
Cancers (Basel), 18 (9)
DOI 10.3390/cancers18091337, PubMed 42122291